1FPC image
Deposition Date 1994-10-16
Release Date 1995-02-27
Last Version Date 2024-10-30
Entry Detail
PDB ID:
1FPC
Title:
ACTIVE SITE MIMETIC INHIBITION OF THROMBIN
Biological Source:
Source Organism:
Hirudo medicinalis (Taxon ID: 6421)
Homo sapiens (Taxon ID: 9606)
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Observed:
0.14
Space Group:
C 1 2 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:thrombin
Gene (Uniprot):F2
Chain IDs:B (auth: H)
Chain Length:259
Number of Molecules:1
Biological Source:Homo sapiens
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:Hirudin
Chain IDs:C (auth: I)
Chain Length:12
Number of Molecules:1
Biological Source:Hirudo medicinalis
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:thrombin
Gene (Uniprot):F2
Chain IDs:A (auth: L)
Chain Length:36
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
TYS C TYR O-SULFO-L-TYROSINE
Ligand Molecules
Peptide-like Molecules
PRD_000376
Primary Citation
Active-site mimetic inhibition of thrombin.
Acta Crystallogr.,Sect.D 51 550 559 (1995)
PMID: 15299843 DOI: 10.1107/S0907444994013132

Abstact

The structures of two mimetic inhibitor complexes of human alpha-thrombin have been determined by X-ray crystallography. One mimics a beta-turn with a bicyclic ring system; the other mimics two different active-site binding modes. The beta-turn mimetic is used to approximate a turn found in the conformation of fibrinopeptide A, which is catalytically released by thrombin in the activation of fibrinogen to fibrin. The binding of the second mimetic is a hybrid between normal substrate and the abnormal binding of the potent natural leech inhibitor hirudin. The binding of the beta-turn mimetic is tenuous, because it is like a substrate, while that of the substrate-hirudin hybrid is that of a tenacious inhibitor (which it is). Structurally retrospect modifications for rational design and improvement of both mimetic inhibitors are proposed.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
Feedback Form
Name
Email
Institute
Feedback